Abstract: The present invention relates to a pharmaceutical composition comprising a therapeutically effective dose of Lenvatinib mesylate having sodium wherein the weight ratio of Lenvatinib mesylate to sodium carbonates ranges from 1:1.5 to 1:5.

Abstract: The present invention relates to a pharmaceutical granulate composition comprising Palbociclib free base, having improved bioavailability.

Abstract: The present invention relates to a pharmaceutical composition comprising pomalidomide, maltodextrin and a filler, wherein the weight ratio of maltodextrin to filler ranges from 1:1 to 1:2. The invention further relates to the use of said pharmaceutical composition as medicament in the treatment of multiple myeloma.

Abstract: The present invention relates to a pharmaceutical composition comprising amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, with a synthetic antioxidant and one or more pharmaceutically acceptable excipients. The invention further relates to the process to manufacture such a compositions and the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodyplastic syndromes.

Abstract: The present invention relates to a pharmaceutical composition comprising a therapeutically effective dose of Lenvatinib mesylate having sodium wherein the weight ratio of Lenvatinib mesylate to sodium carbonates ranges from 1:1.5 to 1:5.

Abstract: The present invention relates to a pharmaceutical granulate composition comprising Palbociclib free base, having improved bioavailability.

Abstract: The present invention relates to a pharmaceutical composition comprising a physical mixture of sacubitril sodium and valsartan disodium, wherein the X-ray powder diffraction pattern of valsartan disodium comprises characteristic peaks at the following 2 theta (±0.2) angles: 4.70°, 9.29°, 22.34°, measured using a Cu K? radiation. The invention further relates to the use of said pharmaceutical composition as medicament in the treatment of heart failure.

Abstract: The present invention relates to a pharmaceutical composition, particularly a modified release tablet composition comprising mirabegron or a pharmaceutically acceptable salt thereof and to a process for preparing such a composition.

Abstract: The present invention relates to a pharmaceutical composition, particularly a modified release tablet composition comprising mirabegron or a pharmaceutically acceptable salt thereof and to a process for preparing such a composition.

Abstract: The present invention relates to a pharmaceutical multi layer tablet comprising a controlled release part with mirabegron and an immediate release part wherein the immediate release formulation comprises: solifenacin succinate and a water insoluble diluent in an amount of 50 to 99% w/w relative to the total weight of the immediate release part of the tablet. The invention further relates to the use of said composition as a medicament, particularly in the treatment of urinary incontinence.

Abstract: The present invention relates to a pharmaceutical composition comprising amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, with a synthetic antioxidant and one or more pharmaceutically acceptable excipients. The invention further relates to the process to manufacture such a compositions and the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodyplastic syndromes.

Abstract: The present invention relates to a pharmaceutical composition comprising amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, with a synthetic antioxidant and one or more pharmaceutically acceptable excipients. The invention further relates to the process to manufacture such a compositions and the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodyplastic syndromes.

Abstract: The present invention relates to a pharmaceutical composition comprising pomalidomide, maltodextrin and a filler, wherein the weight ratio of maltodextrin to filler ranges from 1:1 to 1:2. The invention further relates to the use of said pharmaceutical composition as medicament in the treatment of multiple myeloma.

Abstract: The present invention relates to a pharmaceutical composition, particularly a modified release tablet composition comprising mirabegron or a pharmaceutically acceptable salt thereof and to a process for preparing such a composition.

Abstract: The present invention relates to a pharmaceutical composition, particularly a modified release tablet composition comprising mirabegron or a pharmaceutically acceptable salt thereof and to a process for preparing such a composition

Abstract: The present invention relates to a pharmaceutical composition comprising a physical mixture of sacubitril sodium and valsartan disodium, wherein the X-ray powder diffraction pattern of valsartan disodium comprises characteristic peaks at the following 2 theta (±0.2) angles: 4.70°, 9.29°, 22.34°, measured using a Cu K? radiation. The invention further relates to the use of said pharmaceutical composition as medicament in the treatment of heart failure.

Abstract: The present invention relates to a pharmaceutical composition comprising amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, with a synthetic antioxidant and one or more pharmaceutically acceptable excipients. The invention further relates to the process to manufacture such a compositions and the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodyplastic syndromes.

Abstract: The present invention provides an anhydrous liquid tooth whitening composition comprising a peroxide-containing compound and an orally acceptable carrier wherein the carrier includes a humectant, a bioadhesive agent, and a film-forming agent consisting essentially of a water-insoluble film-forming agent and a solvent for the film-forming agent.

Abstract: The present invention provides a dissolvable strip for whitening teeth. The strip, which is preferably a single layer, has a whitening agent and a water-soluble or water dispersible polymer system. The dissolution of the whitening composition is controlled by interaction of the whitening composition with an oral environment containing saliva. The present invention further provides a process for preparing the whitening strip in the form of a dry film and a method of whitening teeth.

Abstract: There are described devices implantable in the human or animal body. Such a device takes the form of a pre-formed three-dimensional article, comprising at least in part a material which is hydratable and capable of bonding to tissue whilst retaining its integrity. The material may be activated, leading to cross-linking of the material and the formation of chemical bonds between the material and tissue to which it is applied. In preferred embodiments the material has self-adhesive properties. The article may have a wide variety of shapes to suit its intended purpose, and may be manufactured by a variety of methods.